AIM News and Press, AIM ImmunoTech Inc. From 03/22/21

OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase 1/2a study e...

The following slide deck was published by AIM ImmunoTech Inc. in conjunction with this event. For further details see: AIM ImmunoTech (AIM) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow

OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit. About The Investor Summit ...

AIM ImmunoTech (AIM) has dosed the first healthy subjects in its Phase 1 clinical study on the safety of Ampligen as a potential intranasal therapy.AIM’s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage treatment for COVID-19 and other respiratory viral ...

OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ’s goal is t...

OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021. ...

4 Biotech Penny Stocks to Watch Right Now Over the past twelve months, interest in biotech penny stocks has continued to see new peaks. While this is partly due to the pandemic’s effects, it seems that it goes beyond this. Due to Covid, a massive influx of capital has come in...

AIM ImmunoTech (AIM) company NV Hemispherx Biopharma Europe, has received formal notification from the European Commission ((EC)) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.Shares of the company were trading up nearly&...

OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application...

OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal the...